Steven Cohen’s Ocular Therapeutix OCUL Stock Holding History

Steven Cohen’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.3M	Sell	3,292,193 -2,242,792	-41%	-$20.3M	0.04%	619
2026 Q1	$46.9M	Buy	5,534,985 +4,518,737	+445%	+$43.1M	0.06%	403
2025 Q4	$12.3M	Sell	1,016,248 -3,585,073	-78%	-$43.5M	0.01%	1229
2025 Q3	$53.8M	Buy	4,601,321 +2,697,107	+142%	+$32.3M	0.09%	254
2025 Q2	$17.7M	Sell	1,904,214 -38,148	-2%	-$299K	0.03%	542
2025 Q1	$14.2M	Sell	1,942,362 -993,562	-34%	-$7.64M	0.03%	549
2024 Q4	$25.1M	Buy	2,935,924 +895,304	+44%	+$8.73M	0.06%	385
2024 Q3	$17.8M	Sell	2,040,620 -666,043	-25%	-$5.49M	0.05%	453
2024 Q2	$18.5M	Buy	+2,706,663	New	+$16.7M	0.05%	418
2022 Q4	–	Sell	-1,000	Closed	-$4K	–	1713
2022 Q3	$4K	Sell	1,000 -49,000	-98%	-$247K	﹤0.01%	1353
2022 Q2	$201K	Buy	+50,000	New	+$189K	﹤0.01%	1284

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's OCUL Position: Q2 2026 in Review

Steven Cohen reduced its Ocular Therapeutix (OCUL) stake by 41% in Q2 2026, selling an estimated $20.3M and leaving 3,292,193 shares worth $32.3M. The position accounts for 0.04% of the portfolio, ranked #619.

Steven Cohen first reported a position in OCUL in Q2 2022 and has held it in 11 quarters since. The position peaked at $53.8M in Q3 2025. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Steven Cohen held 3,292,193 shares of Ocular Therapeutix worth $32.3M as of Q2 2026.
Steven Cohen sold 2,242,792 Ocular Therapeutix shares in Q2 2026, an estimated $20.3M.
Ocular Therapeutix made up 0.04% of Steven Cohen's portfolio in Q2 2026, its #619 holding.
Steven Cohen first reported a position in Ocular Therapeutix in Q2 2022 and has held it in 11 quarters since.
Steven Cohen's Ocular Therapeutix position peaked at $53.8M in Q3 2025.
260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.